Inmune Bio (INMB)
NASDAQ:INMB
Want to see INMB full AI Analyst Report?
Top Page
Inmune Bio
(NASDAQ:INMB)
Select Model
Select Model
Rating:53Neutral
Price Target:
$1.50
▼(-1.96% Downside)
Action:ReiteratedDate:05/09/26
The score is held back mainly by weak financial performance (pre-commercial profile with persistent losses and cash burn despite low leverage). Offsetting this is a constructive earnings update with concrete regulatory/manufacturing milestones and improved quarterly loss, while technicals are neutral-to-slightly positive and valuation is constrained by a negative P/E and no dividend.
Positive Factors
Regulatory Progress
Concrete regulatory milestones (PIP rapid assessment, MAA documentation and planned MHRA/parallel EMA‑FDA filings) materially de‑risk the pathway to approval. Over the next 6–18 months these durable regulatory actions increase the chance of commercialization and make the programs more partnerable and financeable.
Negative Factors
Pre-commercial Losses
The company remains pre‑commercial with negligible revenue and sustained large net losses, indicating no self‑sustaining operating cash generation. Over multiple quarters this structural deficit necessitates external capital and weakens financial resilience, increasing dependency on dilutive financing or partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Progress
Concrete regulatory milestones (PIP rapid assessment, MAA documentation and planned MHRA/parallel EMA‑FDA filings) materially de‑risk the pathway to approval. Over the next 6–18 months these durable regulatory actions increase the chance of commercialization and make the programs more partnerable and financeable.
Read all positive factors
Inmune Bio (INMB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$38.02M
Dividend YieldN/A
Average Volume (3M)421.60K
Price to Earnings (P/E)―
Beta (1Y)0.95
Revenue Growth-100.00%
EPS Growth13.12%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.69
Shares Outstanding26,585,258
10 Day Avg. Volume317,005
30 Day Avg. Volume421,597
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.76
Price to Sales (P/S)829.46
P/FCF Ratio-1.76
Enterprise Value/Market Cap0.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-324.44
Enterprise Value/Ebitda-0.68
Forecast
1Y Price Target
$8.00Price Target Upside422.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.77
Revenue Forecast (FY)N/A
Inmune Bio Business Overview & Revenue Model
Company Description
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, s...
How the Company Makes Money
null...
Inmune Bio Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Neutral
The call conveyed meaningful, tangible progress toward a key inflection point: CORDStrom advanced through regulatory planning (PIP approval), manufacturing validation runs began, and a long-term supply agreement was secured — all supportive milestones. XPro imaging work and partnership exploration were also positive. Offsetting these positives are schedule/regulatory timing shifts, a materially limited cash runway (funding through Q1 2027), and a large year-over-year reduction in R&D spend that could indicate slower near-term investment. Overall the call shows constructive execution on regulatory and manufacturing fronts but meaningful financing and execution risks remain.Positive Updates
CORDStrom regulatory progress (PIP and MAA preparation)
Submitted Pediatric Investigation Plan (PIP) to U.K. regulator; approved for rapid assessment with response received April 9 and no substantial issues raised. Marketing Authorization Application (MAA) documentation across five sections is well underway; company expects to submit to MHRA in early Q3 and is targeting parallel EMA/FDA filings to meet the previously stated end-of-year filing timeline.
Negative Updates
Minor regulatory delays shifting MHRA timing
Management disclosed 'some minor regulatory delays' that moved the planned MHRA submission to early Q3 rather than earlier in the year, introducing schedule risk to the previously communicated timeline.
Read all updates
Q1-2026 Updates
Positive
Negative
CORDStrom regulatory progress (PIP and MAA preparation)
Submitted Pediatric Investigation Plan (PIP) to U.K. regulator; approved for rapid assessment with response received April 9 and no substantial issues raised. Marketing Authorization Application (MAA) documentation across five sections is well underway; company expects to submit to MHRA in early Q3 and is targeting parallel EMA/FDA filings to meet the previously stated end-of-year filing timeline.
Read all positive updates
Company Guidance
Management guided that CORDStrom remains on track for regulatory filings, expecting to submit to the U.K. MHRA in early Q3 2026 and to pursue parallel EMA/FDA submissions (TMC Pharma retained) with an end‑of‑year 2026 filing target and commercial manufacturing/supply planned for 2027; manufacturing validation has begun (first of 3 process‑validation runs started on time, two remaining scheduled), the pediatric investigation plan received a rapid assessment with regulator response on April 9 and a final response due shortly, and an amended material transfer agreement with Anthony Nolan to secure umbilical cord supply was signed; financial guidance/metrics included Q1 2026 net loss of ~ $5.4M (vs. ~$9.7M Q1 2025), R&D spend of ~ $3.6M (vs. ~$7.6M), G&A of ~ $2.2M (vs. ~$2.3M), cash and cash equivalents of ~ $21.4M as of March 31, 2026 with runway into Q1 2027, and ~26.6M shares outstanding as of May 7, 2026.Inmune Bio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
64
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 50.00K | 14.00K | 155.00K | 374.00K | 181.00K |
| Gross Profit | -56.00K | 50.00K | 14.00K | 155.00K | 374.00K | 181.00K |
| EBITDA | -26.72M | -30.79M | -42.08M | 0.00 | 0.00 | 0.00 |
| Net Income | -41.60M | -45.93M | -42.08M | -30.01M | -27.30M | -30.34M |
Balance Sheet | ||||||
| Total Assets | 25.82M | 32.35M | 39.56M | 57.00M | 81.80M | 99.94M |
| Cash, Cash Equivalents and Short-Term Investments | 21.36M | 24.75M | 20.92M | 35.85M | 52.15M | 74.81M |
| Total Debt | 1.51M | 1.03M | 384.00K | 10.44M | 15.31M | 15.23M |
| Total Liabilities | 6.19M | 8.83M | 7.46M | 18.86M | 21.69M | 19.72M |
| Stockholders Equity | 19.62M | 23.52M | 32.10M | 38.14M | 60.10M | 80.22M |
Cash Flow | ||||||
| Free Cash Flow | -20.78M | -23.62M | -33.36M | -11.98M | -22.69M | -43.50M |
| Operating Cash Flow | -19.17M | -22.58M | -33.36M | -11.98M | -22.69M | -28.50M |
| Investing Cash Flow | -1.04M | -1.04M | 0.00 | 0.00 | 0.00 | -15.00M |
| Financing Cash Flow | 22.34M | 27.61M | 18.21M | -4.22M | 729.00K | 96.36M |
Inmune Bio Technical Analysis
Neutral
1.53
Price Trends
1.31
Positive
1.51
Negative
1.80
Negative
Market Momentum
<0.01
Negative
63.03
Neutral
95.29
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INMB, the sentiment is Neutral. The current price of 1.53 is above the 20-day moving average (MA) of 1.24, above the 50-day MA of 1.31, and below the 200-day MA of 1.80, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 63.03 is Neutral, neither overbought nor oversold. The STOCH value of 95.29 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for INMB.
Inmune Bio Risk Analysis
Inmune Bio disclosed 59 risk factors in its most recent earnings report. Inmune Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Inmune Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $38.02M | -1.39 | -171.01% | ― | -100.00% | 13.12% | |
52 Neutral | $113.94M | 5.20 | -165.19% | ― | 195.75% | 58.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $194.77M | -0.32 | 77.87% | ― | 0.57% | -76.41% | |
46 Neutral | $35.95M | -2.04 | -83.24% | ― | -100.00% | 48.16% | |
42 Neutral | $25.47M | -0.31 | 763.31% | ― | -51.03% | -35.20% |
* Healthcare Sector Average
INMB
Inmune Bio
1.43
-5.54
-79.48%
VERU
Veru
2.24
-2.80
-55.56%
KPTI
Karyopharm Therapeutics
8.64
2.63
43.76%
CUE
Cue Biopharma
35.00
11.61
49.64%
CELU
Celularity
0.88
-0.79
-47.37%
JUNS
Jupiter Neurosciences, Inc.
0.33
-0.29
-46.45%
Inmune Bio Corporate Events
Business Operations and Strategy
INmune Bio Expands Cord Tissue License for CORDStrom Platform
Positive
May 5, 2026
On April 29, 2026, INmune Bio Inc. and its UK subsidiary INmune Bio International entered into an amended and restated material transfer and license agreement with UK charity Anthony Nolan, formalizing INmune Bio as a party and making it jointly l...
Business Operations and StrategyProduct-Related Announcements
INmune Bio Highlights CORDStrom RDEB Program and IP Strength
Positive
Feb 27, 2026
INmune Bio has released a new corporate slide presentation dated March 2025 outlining its late-stage pipeline in inflammation and immunology, with an emphasis on CORDStrom as a systemic therapy for the ultra-rare skin disorder RDEB and XPro1595 fo...
Business Operations and StrategyProduct-Related Announcements
INmune Bio Advances XPro Toward Registrational Alzheimer’s Study
Positive
Feb 23, 2026
INmune Bio Inc., a clinical-stage biotechnology company specializing in inflammation and immunology, is advancing a pipeline that includes CORDStrom™ for rare dermatologic disease, XPro™ as a selective soluble TNF inhibitor targeting n...
Business Operations and StrategyProduct-Related Announcements
INmune Bio to Present New CORDStrom Phase III Data
Positive
Feb 19, 2026
On February 19, 2026, INmune Bio announced plans to host a webinar on February 26, 2026, to present new clinical data on its CORDStrom cell therapy candidate for recessive dystrophic epidermolysis bullosa. The MissionEB Phase III trial data to be ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
INmune Bio Advances CORDStrom Toward Rare Disease Commercialization
Positive
Feb 13, 2026
On February 10, 2026, INmune Bio submitted a pre-submission package to the U.K. Medicines and Healthcare Products Regulatory Agency for CORDStrom, a potential first systemic therapy for recessive dystrophic epidermolysis bullosa, following encoura...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.